According to Sun Pharma, the FDA has approved an Abbreviated New Drug Application (ANDA) for a generic version of azelastine nasal spray submitted by a Sun subsidiary. Sun notes that the US sales of azelastine nasal spray are about $144 million annually.
Astelin and Astepro azelastine sprays are distributed in the US by Meda. Astepro is a newer formulation approved in 2009, and Meda got a new patent for that product as recently as December 2011.
Read the Sun Pharma press release.
